Logo

The efficacy of the Rességuier method in the treatment of fibromyalgia syndrome: a randomized controlled trial

, , , , , , ,

Department of BioMedicine, Division of Rheumatology, Denothe Centre, Careggi Hospital (AOUC), University of Florence, Italy. s.maddali@dac.unifi.it

CER698 Submission on line
2010 Vol.28, N°6 ,Suppl.63 - PI 0046, PF 0050
Full Papers

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

Abstract

OBJECTIVES:
In fibromyalgia syndrome (FMS) defined rehabilitation guidelines are yet to be validated. Our aim is to evaluate the efficacy of the Rességuier method (RM) in FMS.
METHODS:
Forty-one patients were randomly assigned to Interventional (22 pts) and Observational (19 pts) Group (IG and OG). The study lasted 8 months. Patients were assessed at baseline (T0) after a 2-month rehabilitation (T1) and at a 6-month follow-up (T2) (only IG) with SF-36 Physical (PSI) and Mental Synthetic Index (MSI), Regional Pain Scale (RPS), Fibromyalgia Impact Questionnaire (FIQ), Number Rating Scales 0-10 to measure pain, movement quality, sleep, relax ability, analgesics number/per week. OG patients maintained their lifestyle for the duration of the study. RM aims to obtain patient awareness and control of bodily perceptions, thus reaching a modulation of responses to pain. Therapist controls patient attention and perception by verbal and manual contacts and leads them to perform bodily and respiratory active and conscious movements.
RESULTS:
In IG, at T1 all items were improved: PSI and MSI (p<0.001 and =0.001), FIQ (p<0.0001), RPS (p<0.001), pain (p<0.0001), movement quality (p=0.001), relax ability (p<0.0001), sleep (p<0.001); analgesics number/per week was reduced (p<0.001). All results obtained at T1, except FIQ, were maintained at T2. In OG at T1 versus T0, no difference in any of the assessed parameters was observed. CONCLUSION. In FMS patients, the rehabilitation with RM improves HRQoL, FMS-related disability and perceived pain, thus reducing the assumption of analgesics.

PMID: 21122269 [PubMed]

Received: 05/11/2009 - Accepted : 22/03/2010 - In Press: 22/12/2010 - Published: 20/12/2010